Allis, Grunstein, Glen, Steitz win 2018 Lasker Awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
C. David Allis
Michael Grunstein
John B. Glen
Joan Argetsinger Steitz

The Albert and Mary Lasker Foundation announced Sept. 11 the winners of its 2018 Lasker Awards:

  • C. David Allis from Rockefeller University and Michael Grunstein from the University of California, Los Angeles will receive the Albert Lasker Basic Medical Research Award, for discoveries elucidating how gene expression is influenced by chemical modification of histones—the proteins that package DNA within chromosomes.

  • John B. Glen, formerly from AstraZeneca, will be honored with the Lasker~DeBakey Clinical Medical Research Award, for the discovery and development of propofol, a chemical whose rapid action and freedom from residual effects have made it the most widely used agent for induction of anesthesia in patients throughout the world.

  • Joan Argetsinger Steitz from Yale University will receive the Lasker~Koshland Special Achievement Award in Medical Science, for four decades of leadership in biomedical science—exemplified by pioneering discoveries in RNA biology, generous mentorship of budding scientists, and vigorous and passionate support of women in science.

Widely regarded as America’s top biomedical research prize, the Lasker Awards carry an honorarium of $250,000 for each category. The awards will be presented Friday, Sept. 21, in New York City.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login